Ocular Therapeutix

Ocular Therapeutix, Inc. is a biopharmaceutical company specializing in the development and commercialization of innovative therapies for eye diseases and conditions. They generate revenue through the sale of their FDA-approved products, such as DEXTENZA, an intracanalicular insert for post-surgical ocular pain, and ReSure Sealant, used in ophthalmic surgeries. Founded in 2006, the company has a strong focus on sustained-release drug delivery technology, which aims to improve patient outcomes by reducing the frequency of treatments. Their pipeline includes treatments for glaucoma, allergic conjunctivitis, and other ocular conditions, positioning them as a leader in ophthalmic therapeutics.

Recent Posts by Ocular Therapeutix

1-20 of 61